Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs GSK plc (GSK) Price & Performance

Brunswick CorporationTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs GSK plc — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 19.4× Brunswick Corporation's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

BCGSK
Market Cap
$5.28B$102.60B
Sector
Consumer CyclicalHealth
52-Week High
$89.22$61.18
52-Week Low
$58.75$38.22
Enterprise Value
$7.28B$123.04B
Dividend Yield
2.16%3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.

The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK